Dr. Reddy’s Srikakulam plant gets USFDA VAI clearance
Dr. Reddy’s Laboratories received voluntary action indicated status from the U.S. Food and Drug Administration for its Srikakulam manufacturing plant in Andhra Pradesh. The Hyderabad pharmaceutical company told stock exchanges it obtained the establishment inspection report on Oct. 20 after regulators completed their review. The classification means federal health officials identified concerns but will not pursue enforcement measures or administrative penalties against the facility.
The voluntary action indicated designation ranks better than official action, indicating a status that triggers warning letters or import restrictions. Inspectors examined the Srikakulam site for good manufacturing practices compliance and conducted pre-approval assessments. Company shares climbed 2.10 percent to close at 1,282.40 rupees on Monday following the announcement.
The stock gained 45.90 rupees over five trading sessions for a 3.7 percent increase. Shares fell 16.40 rupees in the past month and dropped 54.48 rupees over 12 months. The pharmaceutical maker has lost approximately 6 percent of its value through 2025 but posted gains of 107.60 rupees across six months.
